Predicting Determinants of Atrial Fibrillation or Flutter for Therapy Elucidation in Patients at Risk for Thromboembolic Events (PREDATE AF) Study

      Background

      Atrial fibrillation (AF) is the most common clinically significant cardiac rhythm disorder. There is considerable interest in screening for AF, as it is a leading cause of stroke, and oral anticoagulants (OACs) have been shown to significantly reduce the risk of stroke in patients with AF. Improved screening for AF with subsequent treatment may help improve long-term outcomes, but the optimal patient population and screening intensity are unknown.

      Objectives

      In this study, we prospectively evaluated the use of the CHA2DS2-VASc score for the prediction of new-onset AF using insertable cardiac monitors (ICMs) and examined whether this screening led to the initiation of OAC therapy.

      Methods

      We enrolled 245 subjects with no history of AF and CHA2DS2-VASc score ≥2 to be screened for AF with an ICM. The ICMs were programmed to record AF episodes ≥6 minutes in duration. Subjects were followed for 18 months with monthly remote interrogations and all events adjudicated by cardiologists. In subjects diagnosed with AF, medical records were reviewed to determine subsequent care.

      Results

      During a mean follow-up of 451 ± 185 days, the incidence of AF was 22.4% (95% confidence interval 17.2%–27.7%) with a mean time to detection of 141.3 ± 139.5 days. Among subjects newly diagnosed with AF, 76.4% were prescribed anticoagulation with either a novel OAC (n = 38) or warfarin (n = 4).

      Conclusion

      In this large prospective cohort of subjects with CHA2DS2-VASc scores ≥2, 22.4% were newly diagnosed with AF and the majority of these subjects were given OACs, suggesting a potential role of ICMs in AF screening.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mozaffarian D.
        • Benjamin E.J.
        • Go A.S.
        • et al.
        Heart disease and stroke statistics—2015 update: a report from the American Heart Association.
        Circulation. 2015; 131: e29-e39
        • Lloyd-Jones D.M.
        • Wang T.J.
        • Leip E.P.
        • Larson M.G.
        • Levy D.
        • Vasan R.S.
        • D’Agostino R.B.
        • Massaro J.M.
        • Beiser A.
        • Wolf P.A.
        • Benjamin E.J.
        Lifetime risk for development of atrial fibrillation.
        Circulation. 2004; 110: 1042-1046
        • Marini C.
        • De Santis F.
        • Sacco S.
        • Russo T.
        • Olivieri L.
        • Totaro R.
        • Carolei A.
        Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study.
        Stroke. 2005; 36: 1115-1119
        • Sanna T.
        • Diener H.-C.
        • Passman R.S.
        • et al.
        Cryptogenic stroke and underlying atrial fibrillation.
        N Engl J Med. 2014; 370: 2478-2486
        • Leyden J.M.
        • Kleinig T.J.
        • Newbury J.
        • Castle S.
        • Cranefield J.
        • Anderson C.S.
        • Crotty M.
        • Whitford D.
        • Jannes J.
        • Lee A.
        • Greenhill J.
        Adelaide stroke incidence study.
        Stroke. 2013; 44: 1226-1231
        • Granger C.B.
        • Alexander J.H.
        • McMurray J.J.V.
        • et al.
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Hart R.G.
        • Pearce L.A.
        • Aguilar M.I.
        Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.
        Ann Intern Med. 2007; 146: 857-867
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • et al.
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Patel M.R.
        • Mahaffey K.W.
        • Garg J.
        • et al.
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Kirchhof P.
        • Benussi S.
        • Kotecha D.
        • et al.
        2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
        Eur Heart J. 2016; 37: 2893-2962
        • Kernan W.N.
        • Ovbiagele B.
        • Black H.R.
        • et al.
        Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack.
        Stroke. 2014; 45: 2160-2236
        • Svennberg E.
        • Engdahl J.
        • Al-Khalili F.
        • Friberg L.
        • Frykman V.
        • Rosenqvist M.
        Mass screening for untreated atrial fibrillation: the STROKESTOP study.
        Circulation. 2015; 131: 2176-2184
        • Engdahl J.
        • Andersson L.
        • Mirskaya M.
        • Rosenqvist M.
        Stepwise screening of atrial fibrillation in a 75-year-old population.
        Circulation. 2013; 127: 930-937
        • Schnabel R.B.
        • Sullivan L.M.
        • Levy D.
        • et al.
        Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study.
        Lancet. 2009; 373: 739-745
        • Chamberlain A.M.
        • Agarwal S.K.
        • Folsom A.R.
        • Soliman E.Z.
        • Chambless L.E.
        • Crow R.
        • Ambrose M.
        • Alonso A.
        A clinical risk score for atrial fibrillation in a biracial prospective cohort.
        Am J Cardiol. 2011; 107: 85-91
        • Chyou J.Y.
        • Hunter T.D.
        • Mollenkopf S.A.
        • Turakhia M.P.
        • Reynolds M.R.
        Individual and combined risk factors for incident atrial fibrillation and incident stroke: an analysis of 3 million at-risk US patients.
        J Am Heart Assoc. 2015; 4: e001723
        • Brunner K.J.
        • Bunch T.J.
        • Mullin C.M.
        • May H.T.
        • Bair T.L.
        • Elliot D.W.
        • Anderson J.L.
        • Mahapatra S.
        Clinical predictors of risk for atrial fibrillation: implications for diagnosis and monitoring.
        Mayo Clin Proc. 2014; 89: 1498-1505
        • Saliba W.
        • Gronich N.
        • Barnett-Griness O.
        • Rennert G.
        Usefulness of CHADS2 and CHA2DS2-VASc scores in the prediction of new-onset atrial fibrillation: a population-based study.
        Am J Med. 2016; 129: 843-849
        • Chao T.-F.
        • Liu C.-J.
        • Chen S.-J.
        • Wang K.-L.
        • Lin Y.-J.
        • Chang S.-L.
        • Lo L.-W.
        • Hu Y.-F.
        • Tuan T.-C.
        • Wu T.-J.
        • Chen T.-J.
        • Chen S.-A.
        CHADS2 score and risk of new-onset atrial fibrillation: a nationwide cohort study in Taiwan.
        Int J Cardiol. 2013; 168: 1360-1363
        • Hindricks G.
        • Pokushalov E.
        • Urban L.
        • et al.
        Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: results of the XPECT trial.
        Circ Arrhythm Electrophysiol. 2010; 3: 141-147
        • Lip G.Y.H.
        • Nieuwlaat R.
        • Pisters R.
        • Lane D.A.
        • Crijns H.J.G.M.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation.
        Chest. 2010; 137: 263-272
        • Lowres N.
        • Neubeck L.
        • Redfern J.
        • Freedman S.B.
        Screening to identify unknown atrial fibrillation: a systematic review.
        Thromb Haemost. 2013; 110: 213-222
        • Healey J.S.
        • Connolly S.J.
        • Gold M.R.
        • et al.
        Subclinical atrial fibrillation and the risk of stroke.
        N Engl J Med. 2012; 366: 120-129
      1. Reiffel JA. REVEAL AF: incidence of AF in high risk patients. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT01727297. Cited October 21, 2016. Accessed January 3, 2017.

      2. Healey JS, Alings M, Leong-Sit P, DeGraff J, Birnie D, Freericks M, Ha A, Verma A. Prevalence of sub-clinical atrial fibrillation using an implantable cardiac monitor in patients with cardiovascular risk factors: ASSERT II. Abstract presented at: American Heart Association’s Scientific Sessions 2016; November 15, 2016; New Orleans, LA.

        • Lowres N.
        • Neubeck L.
        • Salkeld G.
        • et al.
        Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies: the SEARCH-AF study.
        Thromb Haemost. 2014; 111: 1167-1176
        • Cullen M.W.
        • Kim S.
        • Piccini J.P.
        • et al.
        Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
        Circ Cardiovasc Qual Outcomes. 2013; 6: 461-469
        • Glotzer T.V.
        • Daoud E.G.
        • Wyse D.G.
        • Singer D.E.
        • Ezekowitz M.D.
        • Hilker C.
        • Miller C.
        • Qi D.
        • Ziegler P.D.
        The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study.
        Circ Arrhythm Electrophysiol. 2009; 2: 474-480
        • Boriani G.
        • Glotzer T.V.
        • Santini M.
        • West T.M.
        • De Melis M.
        • Sepsi M.
        • Gasparini M.
        • Lewalter T.
        • Camm J.A.
        • Singer D.E.
        Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project.
        Eur Heart J. 2014; 35: 508-516
        • Shanmugam N.
        • Boerdlein A.
        • Proff J.
        • Ong P.
        • Valencia O.
        • Maier S.K.G.
        • Bauer W.R.
        • Paul V.
        • Sack S.
        Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure–cardiac resynchronization therapy population.
        Europace. 2012; 14: 230-237
        • Glotzer T.V.
        • Hellkamp A.S.
        • Zimmerman J.
        • Sweeney M.O.
        • Yee R.
        • Marinchak R.
        • Cook J.
        • Paraschos A.
        • Love J.
        • Radoslovich G.
        • Lee K.L.
        • Lamas G.A.
        Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke.
        Circulation. 2003; 107: 1614-1619
        • Wolf P.A.
        • Abbott R.D.
        • Kannel W.B.
        Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.
        Stroke. 1991; 22: 983-988
      3. Healey J, Connolly S, Alings M, Lopes R. Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA). In: ClinicalTrials.gov. Bethesda, (MD: National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT01938248. Cited October 21, 2016. Accessed January 3, 2017.

      4. Kirchhof P. Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes (NOAH). In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT02618577. Cited October 21, 2016. Accessed January 3, 2017.